8 May 1998
ISBN: N/A
Cat. No.: N/A
(DIR98-04)
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
This Regulatory Directive details the chemistry requirements for registration under the Pest Control Products Act (PCPA) and Regulations and the recommended organization of Part 2 of the data submission. Guidance addressing the submittal of product-related analytical standards is also provided.
This document replaces Regulatory Directive Dir93-02, Chemistry Requirements for the Registration of Technical Active Ingredients, February 18, 1993. The revision process sought industry input through Regulatory Proposal Pro97-01, Chemistry Requirements for the Registration of a Technical Grade of Active Ingredient or an Integrated System Product, published in July 1997. Comments received were considered in the final version of the document.
The chemistry requirements have been harmonized with those of the U.S. Environmental Protection Agency (EPA) as described in the Code of Federal Regulations (CFR), 40 CFR § 158, and the Product Properties Test Guidelines 830 Series.
A tabular correlation between Pest Management Regulatory Agency (PMRA) and EPA guidance documents is provided in Appendix III to aid applicants in the compilation of a complete product chemistry package.
Product chemistry information is developed and submitted for review in order to meet two objectives:
The key requirement for meeting these objectives is the provision of detailed information on the composition of the technical grade of active ingredient (TGAI) or integrated system product (ISP), which is accomplished by submitting intensive analysis to 0.1% w/w with the determination of impurities of toxicological significance at any concentrationFootnote 1. These data are to be accompanied by an explanation of methodology that, on its own merits, permits validation of procedures, results and conclusions. The analytical data must also be supported by a description of all starting materialsFootnote 2 and the manufacturing process used to produce the pest control product.
Regulatory authorities must be able to assess the potential presence of impurities known to have, or suspected to have, health and/or environmental implications. The applicant should carefully consider the two objectives outlined above to ensure that the chemistry data generated will meet the Agency's requirements.
The PMRA has developed a series of Data Codes (DACOs) to address registration requirements on a use-site category (USC) basis. These are to be used as the basis for the chemistry package submission and will be screened for completeness prior to the review of the chemistry data. Complete instructions concerning the submission process are found in two Agency publications, Regulatory Proposals Pro96-01, Management of Submissions Policy, and Pro98-02, Organizing and Formatting a Complete Submission for Pest Control Products, both to be rewritten as Regulatory Directives.
Terminology and acronyms used throughout this document are defined in Appendix V and VI respectively. The use of the term product refers to both a TGAI and an ISP. The individual terms are specifically used where warranted.
Appendix I to this document identifies the data requirements for the registration of a TGAI or an ISP and includes additional guidance where warranted. A distinct Regulatory Directive, Dir98-03, identifies the chemistry requirements for manufacturing concentrates (MAs) and end-use products (EPs) derived from registered TGAIs or ISPs. Since an ISP may be registered for manufacturing and/or end-use, the corresponding chemistry requirements identified in Dir98-03 must also be met if it is to be used directly as an EP.
Please note that these data requirements may be partially or completely superseded by distinct guidance found in other PMRA publications, e.g., for specific pesticide types, including pheromones and microbial pest control agents as per the Registration Handbook for Pest Control Products Under the Pest Control Products Act and Regulations. If in doubt, it is recommended that the applicant confirm the relevance of these guidelines for a specific product with the Agency.
Requirements may be waived for some portions of the data requested in Appendix I, on a case-by-case basis, if the applicant can offer an acceptable written rationale based upon scientific reasoning. Such requests should appear in, or be referenced by the corresponding DACO number.
The PMRA may request additional data concerning any requirement found in this Regulatory Directive, also on a case-by-case basis, if deemed necessary for evaluation purposes.
Pursuant to the Pest Control Products Regulations, the Agency may request that product-related samples be provided by applicants. The PMRA's Laboratory Services maintains a central repository of all analytical standards submitted in response to the following requirements.
For new active ingredients and new sources of registered active ingredients, the following samples are required:
If samples are unstable over a 2-year period, smaller amounts may be sufficient. Replacement samples may be requested after their expiry date.
The following samples may be required by the PMRA:
Some or all of the above samples may be requested for active ingredients in products currently registered under the PCPA, e.g., for active ingredients under re-evaluation, or as required by the PMRA's Laboratory Services to maintain its inventory.
Samples are to be sent directly to:
Laboratory Services
Pest Management Regulatory Agency
Health Canada
Laboratory Services Building, No. 22
Central Experimental Farm
Ottawa, Ontario K1A 0C6
Requirement: Identification information is required as described in Sections 2.1 to 2.10.
Purpose: To clearly identify the product, its active ingredient(s) and source of manufacture.
Guidance: Additional instructions are provided, as warranted, in each section.
The applicant identifies the company that has the ultimate responsibility for certifying the information found on the PMRA Control Product Specification form (CPSF), as distinct from the manufacturing plant, which is addressed in Section 2.2 below.
The actual manufacturer would typically form part of the same company identified in Section 2.1, above, but it could also reflect the use of a toll manufacturer. The manufacturing plant identifies the specific location at which the material is produced.
Include any company development code as well as any equivalent foreign name to which data found in the submission may refer.
Include the International Organization for Standardization (ISO) common name of each active ingredient or, if not as yet established, the proposed name.
Both the International Union of Pure and Applied Chemistry (IUPAC) and Chemical Abstracts names of each active ingredient are to be provided. If applicable, each stereoisomer listed as an active ingredient must be individually identified and have a corresponding structure depicted in Section 2.7, below, showing the stereochemical designation(s).
Registry Number Identify for each active ingredient or each isomer and/or group of isomers, if established.
Provide for each active ingredient including, if applicable, each stereoisomer identified as an active ingredient.
Requirement: Compositional data is required as described in Sections 2.11 to 2.13, below.
Purpose: To generate a comprehensive qualitative and quantitative listing of the ingredients that may be present in a product through knowledge of the starting materials used, the manufacturing process and assessment of the analytical methodology/data upon which the specifications are based. This information is used to support that the material can be consistently manufactured in accordance with the certified limits as expressed on the CPSF.
The Agency also uses composition data when reviewing new products to assess whether a TGAI or an ISP from a new source (manufacturer or manufacturing site), or produced by a new manufacturing method, is identical or substantially similar to any currently registered TGAI or ISP. This determines whether corresponding environmental, toxicological and/or value data with the Agency are relevant or whether new studies must be generated.
In addition, the data is used to ensure that the test material selected used to generate data supporting Parts 4-10 of the registration process is consistent with that identified on the CPSF.
Guidance: Additional instructions are provided below for each of Sections 2.11 to 2.13.
Information may be based upon pilot plant production or initial commercial production but must be updated to reflect current commercial production whenever applicable (see corresponding batch data requirement in clause 2.13.3).
Provide a brief overview of the manufacturing process outlining the major steps and reactants, summarizing the more comprehensive description required by clause 2.11.3 below. This is to include a general characterization of the process, e.g., batch or continuous, and the typical quantity of product produced per batch (or per unit time, if continuous).
The following information is to be provided for each starting material used to produce the active ingredient:
It should be emphasized that an applicant is not required to perform chemical analysis of starting materials to meet the above criteria, but only provide information to which the applicant has, or should have, access.
The information required for formulants, if applicable to an ISP, is consistent with the three requirements identified above for starting materials.
If multiple suppliers are used for starting materials/formulants, specifications for all suppliers should be provided. Changes in suppliers once a product is registered are subject to the requirements of Regulatory Directive Dir94-01, Notification/Non- Notification, or subsequent revisions.
An applicant must submit information on the manufacturing process used to produce the TGAI or ISP at each stage of production resulting in a separately isolated substance, as follows:
Additional requirements are applicable to the manufacturing of stereoisomeric active ingredients. Three types of products may form during the manufacturing of such actives:
For (ii) and (iii), a full description of the stereoselective manufacturing process is to be provided. Stereospecific identity and purity is to be identified for starting materials.
The applicant must provide a discussion of the impurities that may be found in the product and why they may be present. The discussion should be based on established chemical theory and on what the applicant knows about the starting materials and the production process. The thoroughness of the theoretical discussion can be evaluated in parallel with the preliminary analysis data in Section 2.13, below, to assess whether potential impurities would be comprehensively identified by the methodologies used. If the applicant has reason to believe that an impurity the PMRA would consider to be toxicologically significantFootnote 3 may be present, the discussion must include an expanded description of the possible formation of the impurity and the amounts in which it might be present. The following potential sources of impurity formation must be discussed, as applicable:
On a case-by-case basis, the PMRA may require an expanded discussion of potential impurity formation resulting from other potential chemical reactions, involving other ingredients, or at additional points in the production process.
The nominal concentration and corresponding certified limits must be provided for each product component. The nominal concentration is defined as the typical amount of an ingredient present in a pest control product at the time of its production. Both the active ingredient nominal concentration and a corresponding nominal equivalence statement, if applicable, e.g., acid salts, are to be provided.
The product guarantee, identified on the CPSF and appearing on the draft product label, is synonymous with the active ingredient(s) nominal concentration. This number most accurately identifies the amount of active ingredient found in the TGAI or ISP and is subsequently used to establish corresponding enforceable certified limits, as further discussed in clause 2.12.1 below.
Precise identification of impurities present in products at or above 0.1% by weight is required while the components of toxicological concern must be identified at any concentrationFootnote 4. The composition of a minimum of five batches of the product, determined using specific methods and universal detectors, must be provided to support the specifications, as further described in Appendix I, clause 2.13.3. The submission is to include the structural formulae of all specified impurities.
Required (R) and conditionally required (CR) data for the active ingredient(s) and other product components are to be submitted according to the following table:
| TGAI or ISP Component | Common (or TradeFootnote 5) Name | CAS Chemical Name | CAS No. | Component % by Weight (nominal guarantee) | Lower Certified Limit | Upper Certified Limit | Purpose In Product |
|---|---|---|---|---|---|---|---|
| Active ingredient(s) | R | R | R | R | R | R | R |
| Formulants (if applicable to an ISP) | R | R | R | R | R | R | R |
| Impurities of toxicological significance associated with the active ingredient (at any concentrationFootnote 4) | CRFootnote 6 | R | CRFootnote 6 | R | R | Identify as an impurity | |
| Other impurities associated with the active ingredient at ≥ 0.1% | CRFootnote 6 | R | CRFootnote 6 | R | R | Identify as an impurity |
Specifications for the TGAI or ISP are to include stereoselective tests for the identity and purity of stereoisomers. Distinct, suitably validated methodologyFootnote 7 is typically required to establish enantiomeric purity. For all types of stereoisomer mixtures, specified limits are required for each active component. A reference standard of high stereochemical purity should be available for each specified stereoisomer and ideally, reference standards should be available for all other potential stereoisomeric impurities. Limits are to be specified for individual stereoisomeric impurities, as supported by preliminary batch analysis as described in clause 2.13.3, below. The stability of the optically pure/enhanced active ingredient(s) towards chiral inversion or other isomerization is to be investigated and reported as per clause 2.14.13 or 2.14.14, below, as applicable.
Standard certified limits for active ingredients and formulants are based upon nominal concentration, unless an applicant proposes, and justifies, alternate limits which are deemed acceptable by the PMRA. The applicant must propose upper certified limits for impurities as standard certified limits may not be used for such components.
Standard limits are defined in the following table:
| Nominal Concentration of Ingredient | Upper Limit | Lower Limit |
|---|---|---|
| 20.0% < N ≤ 100.0% | N + 3% N | N - 3% N |
| 1.0% < N ≤ 20.0% | N + 5% N | N - 5% N |
| N ≤ 1.0% | N + 10% N | N - 10% N |
An applicant may propose a certified limit for an active ingredient or formulant that differs from the standard limits, but must include an explanation of the basis for the proposed limits, including how the they were established, e.g., sample analysis or a quantitative estimate based upon the production process. Proposed limits should not greatly exceed those actually occurring in the product.
All certified limits must:
If the PMRA finds any certified limit unacceptable (either standard or applicant proposed), the Agency will inform the applicant of its determination and will provide supporting reasons. The PMRA may also require, on a case-by-case basis, any or all of the following:
Specification data are to be submitted on a CPSF that includes a signed and dated Declaration of Applicant certifying that the information is true and complete.
Full instructions on the proper completion of the form are included with the CPSF.
Methodology for specifically identifying and quantifying the active ingredient(s) and impurities present in products at or above 0.1% by weight, or those of toxicological significance at any concentrationFootnote 8, is to be provided. A more thorough discussion of impurities of toxicological significance is provided in clause 2.13.4, below; however, all corresponding analytical methodology is to be reported under this DACO number.
A method capable of separating stereoisomers, when applicable, as identified in Section 2.12, above, is also required and may result in the need for two methods for the active ingredient(s); one for total stereoisomeric content and a second to confirm any specified ratio.
The recommended reporting format for analytical methodology is outlined in Appendix II.
All methodology must have sufficient precision and accuracy to determine whether the amount of the ingredient found in any sample of the product is within its certified limits.
The identity of the active ingredient and each specified impurity must be supported by relevant chromatograms and/or spectra. Ideally, full spectral characterization by mass spectrometry (MS) of each isolated impurity (or on-line determination using gas chromatography/MS or liquid chromatography/MS) by comparison to the spectrum of a corresponding analytical standard is required. However, if an impurity is expected due to its presence in a starting material or formation as a reaction intermediate in the manufacturing process, as discussed by the applicant in clause 2.11.4, above, chromatographic retention time comparison to a corresponding analytical standard, whose identity and structure has been confirmed, is acceptable to support its identity.
The composition of a minimum of five batches of the product, determined using specific methods and universal detectors, must be provided to support the specifications. Corresponding raw data to be submitted includes representative quantitative chromatograms of: (1) standards; and (2) the five batches of the TGAI or ISP that were used to support each specified active ingredient and impurity. Chromatograms must be clearly labelled to identify all analytical parameters and peaks, including those that may represent compounds quantitated by other methods included in the submission.
These samples may represent pilot plant production; however, if production is scaled up at the same location or if a distinct facility/process is used for commercial manufacturing, data from an additional five batches, corresponding to the current location/process, are required to support the specifications.
Analysis for these impurities is required when there is a potential for their presence in starting materials or their formation during the manufacture of the technical active ingredient.
For example, nitrosamine analysis is required when appropriate amines and an identifiable nitrosating agent (including nitrites and nitrates) are present due to the raw materials or manufacturing process utilized. The primary focus is upon smaller molecular weight volatile and nonvolatile nitrosamines, such as N-dimethylnitrosamine (NDMA) and N-nitrosodipropylamine (NDPA) respectively, rather than larger molecules such as nitrosogyphosate or nitrosoureas. It should be noted that inherent contamination would be expected from products whose chemical structure features both amine functionality and nitrosating potential, such as dinitroanilines.
These analyses, when required, should reflect the lowest practical limit of quantitation (LOQ), which will vary according to the sample and chemical, but must at least be below any corresponding applicable regulatory level. Upper certified limits are required for impurities of toxicological significance present above the LOQ.
Any waiver request for not providing such data must be supported by scientific rationale as to why the presence of such impurities can be excluded and will be assessed based upon the nature of the raw materials, chemistry of the active ingredient and the specific manufacturing process.
Impurities and classes of impurities of toxicological concern include, but are not limited to:
Impurities having characteristics of potential toxicological significance may include:
If a product has been analysed for any of these compounds, methodologies, validation data including recovery and Limit of Detection (LOD)/LOQ for expected contaminant(s), or reasonable surrogates if appropriate, and batch data as per clause 2.13.3, are to be provided. Where it is deemed essential for evaluation, such data from pest control products or potential precursors will be requested. Since detection and quantitation limits may vary from case to case, consultation with the PMRA is recommended.
Applicants should contact the Agency's Health Evaluation Division if there is a question about the status of any specific impurity not listed.
Requirement: To provide methodology and observations/values for the properties identified below in 2.14.1 to 2.14.14.
Purpose: Property data are requested for a number of reasons. The requirements include properties that:
Guidance: Protocols for developing the data requirements identified in this section are not included in this document. Applicants should consult protocols developed and published by various agencies, including those referenced in the comparative table below or listed in Appendix IV.
Property data requirements are identified in Table 3.
Methodology must be thoroughly described or a copy of the scientific publication describing the protocol must be included with the submission. A reference to internationally established protocols is sufficient, if followed without deviation, and the specific procedure used is clearly identified for those protocols providing multiple options. Study reports should include a complete presentation of the data, sample calculations and an interpretation of the results. In addition, basic physio-chemical information on individual stereoisomers is to be provided, if applicable; typically, this may include information on melting point, optical rotation, and stability towards inversion. A pure active ingredient (PAI) is equivalent to the analytical standard of active ingredient described under Section 3.0.
Care should be exercised in the selection of appropriate test materials for properties that provide a TGAI or PAI option to ensure data relevance. Typically, as these properties are characteristic of the active principle, the PAI should be used whenever available. This is most important for properties that may be significantly affected by impurities, such as water solubility, particularly in the presence of residual solvents. Conversely, it may be appropriate to use the TGAI if impurities do not significantly impact upon the outcome of the test and if the corresponding detection principle is selective for the PAI. For example, certain vapour pressure protocols may be conducted on either the TGAI or PAI. Regardless of the material used, the purity of the test substance must always be clearly identified in the study report.
| Clause | Property | Test Substance | Property Notes | Ag CanFootnote 9 T-1-255 | EPA (830 Series) | OECDFootnote 10 |
|---|---|---|---|---|---|---|
| 2.14.1 | Colour | TGAIFootnote 11 | 830.6302 | |||
| 2.14.2 | Physical state | TGAIFootnote 11 | 830.6303 | |||
| 2.14.3 | Odour | TGAIFootnote 11 | 830.6304 | |||
| 2.14.4 | Melting point/melting range | TGAIFootnote 11 or PAI | 1 | 830.7200 | 102 | |
| 2.14.5 | Boiling point/boiling range | TGAIFootnote 11 or PAI | 2 | 830.7220 | 103 | |
| 2.14.6 | Density or specific gravity | TGAIFootnote 11 or PAI | 3 | 830.7300 | 109 | |
| 2.14.7 | Water solubility (mg/L) | TGAIFootnote 11 or PAI | 4 | X | 830.7840 830.7860 |
105 |
| 2.14.8 | Solvent solubility (mg/L) | TGAIFootnote 11 or PAI | 5 | 830.1000 | ||
| 2.14.9 | Vapour pressure | TGAIFootnote 11 or PAI | 6 | X | 830.7950 | 104 |
| 2.14.10 | Dissociation constant | TGAIFootnote 11 or PAI | 7 | 830.7370 | 112 | |
| 2.14.11 | Octanol/water partition coefficient | TGAIFootnote 11 or PAI | 8 | X | 830.7550 830.7560 830.7570 |
107 117 |
| 2.14.12 | UV/visible absorption spectra | TGAIFootnote 11 or PAI | 9 | 830.7050 | 101 | |
| 2.14.13 | Stability (temperature, metals) | TGAI | 10,12, 13 | 830.6313 | 113 | |
| 2.14.14 | Storage stability data | ISP | 11, 12 | 830.6317 |
General:
This Appendix is included primarily to address the issue of content and to suggest a consistent format for ease of data review; however, it is the content that is of primary significance and a report need not be rewritten to adapt to the format suggested.
Title/cover page
Table of Contents
Scope
Identify the analyte(s) for which the method has been validated.
Source of method
Include a reference to a published method, such as sources listed in Appendix IV, if applicable.
Analytical principles
Provide a brief description, including the identification of the chemical species determined, the range over which the analyte(s) has (have) been analysed and, for impurities, the limits of detection and sensitivity.
Equipment
List and describe.
Reagents and standards
List and describe source and preparation.
Analytical procedure
Detail in a stepwise fashion, with special emphasis on reagents or procedural steps requiring special precautions to avoid safety or health hazards, including:
Methods of calculation
Describe in a stepwise fashion.
Other
Identify any and all relevant information the applicant considers appropriate to provide a complete and thorough description of the analytical methodology and the means of calculating the results, i.e., critical control points.
Describe the established performance criteria for the method.
Accuracy
Precision
Identify the number of replicates used.
LOD/LOQ
Provide definition used
Selectivity/specificity
Describe tests used to establish the lack of interferences from other product components or from solvents and materials used in the methodology.
Ruggedness testing
If performed.
Limitations
Linear range
These are to be fully referenced to the body of the report and included where appropriate.
Representative chromatograms, spectra, etc.
As applicable and in accordance with Section 2.13 of this appendix.
Other
Any relevant material not fitting into any other sections of this report.
| PMRA Regulatory Directive Dir98-04 | Corresponding EPA Documentation | |||
|---|---|---|---|---|
| Section | Section Title | EPA No. | EPA TitleFootnote 12 | 40 CFR 158 |
| 1.0 | Introduction | 830.1000 | Background for Product Properties Test Guidelines | |
| 2.0 | Product Chemistry Data Requirements | 830.1000 | Background for Product Properties Test Guidelines | |
| 3.0 | Submittal of Samples | 830.1900 | Submittal of Samples | 158.190 |
| 860.1650 | Submittal of Analytical Reference Standards | 158.240 | ||
| Appendix 1 | Data Requirements for Registration (Part 2 of Data Submission) | |||
| 2.1 | Applicant's Name and Office Address | |||
| 2.2 | Manufacturer's Name and Office Address and Manufacturing Plant's Name and Address | |||
| 2.3 | Product Trade Name | 830.1000 | Background for Product Properties Test Guidelines | |
| 2.3.1 Other Names | 830.1000 | Background for Product Properties Test Guidelines | ||
| 2.4 | Common Name | 830.1550 | Product Identity and Composition | 158.155 |
| 2.5 | Chemical Name | 830.1550 | Product Identity and Composition | 158.155 |
| 2.6 | Chemical Abstracts Registry Number | 830.1550 | Product Identity and Composition | 158.155 |
| 2.7 | Structural Formula | 830.1550 | Product Identity and Composition | 158.155 |
| 2.8 | Molecular Formula | 830.1550 | Product Identity and Composition | 158.155 |
| 2.9 | Molecular Weight | 830.1550 | Product Identity and Composition | 158.155 |
| 2.10 | [Reserved] | |||
| 2.11 | Manufacturing Methods | |||
| 2.11.1 Manufacturing Summary | 830.1620 | Description of Production Process | 158.162 | |
| 2.11.2 Description of Starting Materials | 830.1600 | Description of Materials Used to Produce the Product | 158.160 | |
| 2.11.3 Detailed Production Process Description | 830.1620 | Description of Production Process | 158.162 | |
| 2.11.4 Discussion of Formation of Impurities | 830.1670 | Discussion of Formation of Impurities | 158.167 | |
| 2.12 | Specifications | 830.1550 | Product Identity and Composition | 158.155 |
| 2.12.1 Establishing Certified Limits | 830.1750 | Certified Limits | 158.175 | |
| 2.12.2 Control Product Specification Form | 830.1550 | Product Identity and Composition (Confidential Statement of Formula) | 158.155 | |
| 2.13 | Preliminary Analysis | |||
| 2.13.1 Methodology / Validation | 830.1700 | Preliminary Analysis | 158.170 | |
| 2.13.2 Confirmation of Identity | 830.1700 | Preliminary Analysis | 158.170 | |
| 2.13.3 Batch Data | 830.1000 | Background for Product Properties Test Guidelines | 158.170 | |
| 830.1700 | Preliminary Analysis | |||
| 2.13.4 Impurities of Toxicological Concern | 830.1700 | Preliminary Analysis | 158.170 | |
| 2.14 | Chemical and Physical Properties | Various | See Correlation in Appendix I, Section 2.14 | 158.190 |
Applicants should ensure that they have the latest editions of the following documents.
Note: Italicized text found in a definition identifies that the term is also defined in this appendix.
The appropriate level is dictated by the limit of quantitation (LOQ) of the toxic impurity analytical methodology, which is sample/chemical dependent, and must also be below any applicable regulatory limit.
Any substance, including reactants, solvents and catalysts, used to manufacture or purify a pest control product.
See Appendix I, clause 2.13.4, for a more detailed discussion of impurities of toxicological significance.
The appropriate level is dictated by the limit of quantitation (LOQ) of the toxic impurity analytical methodology, which is sample/chemical dependent, and must also be below any applicable regulatory limit.
Include only if a common name is unavailable, such as for certain formulant mixtures.
To be provided if established.
For example, High-Performance Liquid Chromatography, Gas Chromatography, or Capillary Electrophoresis systems capable of resolving chiral substances; or structural conversion to diastereomers.
The appropriate level is dictated by the limit of quantitation (LOQ) of the toxic impurity analytical methodology, which is sample/chemical dependent, and must also be below any established applicable regulatory limit.
Agriculture Canada, Guidelines for Determining Environmental Chemistry and Fate of Pesticides, Trade Memorandum T-1-255, 1987.
OECD: Organisation for Economic Co-operation and Development.
If the TGAI cannot be isolated, i.e., for an ISP, these data are required on the practical equivalent of the TGAI.
The EPA 830 Series of requirements supersede the 1982 Pesticide Assessment Guidelines Subdivision D, Product Chemistry.